Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® ...

There are three different types of thyroid dysfunction associated with IFN treatment: (1) autoimmune (often subclinical) hypothyroidism; (2) destructive thyroiditis; and (3) Graves ...

Welcome to the CytomX Therapeutics fourth-quarter 2024 and financial results call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Take with food in 2 divided doses, with peginterferon alfa-2a. ≥18yrs ... Nonresponders to interferon. Maintain adequate hydration. Nursing mothers: not recommended.

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase ...